LncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence

Abstract

Objectives We investigated the role of long non-coding (lnc) RNA-NEF (neighboring enhancer of FoxA2), a characterized oncogene in cancer biology, in postmenopausal osteoporosis and its diagnostic and prognostic value in this disease. Methods Expression of lncRNA-NEF in plasma was detected by RNA extraction and real-time quantitative PCR. The diagnostic value of lncRNA-NEF and interleukin (IL)-6 for postmenopausal osteoporosis was evaluated by receiver operating characteristic curve analysis, with postmenopausal osteoporosis patients as true positive cases and healthy volunteers as true negative cases. Results We showed that plasma lncRNA-NEF was downregulated and plasma IL-6 was upregulated in postmenopausal osteoporosis patients compared with healthy controls. Altered plasma levels of lncRNA-NEF and IL-6 separated postmenopausal osteoporosis patients from healthy controls, and lncRNA-NEF and IL-6 were inversely and significantly correlated in osteoporosis patients. Patients were divided into high (n = 68) and low lncRNA-NEF (n = 73) groups according to Youden’s index. Patients with high lncRNA-NEF levels required a significantly shorter treatment course and had a lower post-treatment recurrence rate. Conclusion We showed that lncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence. The involvement of lncRNA-NEF in postmenopausal osteoporosis is likely related to IL-6.

Predicting the levels of orcinol glucoside during the treatment of osteoporosis by network pharmacology and molecular docking

“…In this study, we found that OG may activate VEGFA, EGFR, and MAPK1, as their binding a nities for interaction were all <-7.0. Furthermore, IL6 and IL2 are involved not only in in ammatory responses but also in the regulation of bone mineral density, osteoclast differentiation and activation [40][41]. However, our molecular docking results for IL6 and IL2 showed binding a nities of -6.7 and − 6.1 kcal•moL − 1 ; these are higher than − 7.0 kcal•moL − 1 and therefore indicate that OG exerts only weak inhibition on in ammatory responses.…”

Role of LncRNAs and CircRNAs in Bone Metabolism and Osteoporosis

“…LncRNA-Neighboring enhancer of FOXA2 (NEF), which is known to the inhibit Wnt/β-catenin signaling and transforming growth factor-ßTGF-β pathways in cancer cells (Liang et al, 2018;Ju et al, 2019) is also reported in postmenopausal osteoporosis (PMOP) patients in a high concentration. In human BMSCs isolated from PMOP, enforced expression of NEF inhibited the secretion of IL-6, indicating its potential not only in diagnostics, but also as a prognostic biomarker for PMOP (Ma et al, 2019).…”

The roles of miRNA, lncRNA and circRNA in the development of osteoporosis

“…lncRNA-NEF may play a role in osteoporosis by inhibiting IL-6. Studies in postmenopausal osteoporosis showed that a high lncRNA-NEF level was associated with a substantially reduced course of treatment and lower post-treatment recurrence rate [93]. lncRNA NONMMUT037835.2 regulated osteoclastogenesis by negatively regulating RANK expression and inhibiting the NF-κB/MAPK signaling pathway.…”